COMMUNIQUÉS West-GlobeNewswire

Immunomedics Reveals Promising Data for Sacituzumab Govitecan in Patients Heavily Pretreated for Metastatic Estrogen Receptor-Positive Breast Cancer

03/06/2018 - 16:15

Confirmed Overall Response Rate of 31 Percent; with Median Duration of Response of 7.4 Months and Median Progression-free Survival of 6.8 Months CHICAGO, June 03, 2018 (GLOBE NEWSWIRE) -- Immunomedics, Inc. , (NASDAQ: [...]

Third Novartis Phase III trial shows Kisqali® combination therapy significantly improves PFS in HR+/HER2- advanced breast cancer

03/06/2018 - 15:01

Kisqali plus fulvestrant demonstrated superior efficacy, with a median PFS of 20.5 months vs. 12.8 months for fulvestrant alone, among overall study population of first- and second-line postmenopausal patients with HR+/ [...]

Epizyme Presents Encouraging Phase 2 Data of Tazemetostat for Malignant Mesothelioma at ASCO

03/06/2018 - 15:00

Disease Control Rate of 51 Percent Achieved at 12 Weeks Represents the First Reported Clinical Data of an EZH2 Inhibitor in Patients with Relapsed/Refractory Malignant Mesothelioma CAMBRIDGE, Mass., June 03, 2018 (GLOBE [...]

TLC Submits IND to US FDA Application for TLC178, Liposomal Vinorelbine Candidate for Pediatric Rhabdomyosarcoma

03/06/2018 - 07:00

TAIPEI, Taiwan, June 03, 2018 (GLOBE NEWSWIRE) -- Taiwan Liposome Company, Ltd. (4152.TWO) (TLC), a clinical-stage specialty pharmaceutical company dedicated to the development and commercialization of novel [...]

Celldex Presents Promising Data from Phase 1/2 Study of Varlilumab and Opdivo® at 2018 ASCO Annual Meeting

02/06/2018 - 22:12

-- CDX-3379 also featured in a “clinical trials in progress” presentation -- HAMPTON, N.J., June 02, 2018 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today presented two programs at the 2018 American [...]

Updated Data from Ivosidenib Phase 1 Dose-Escalation and Expansion Trial in IDH1m Relapsed or Refractory AML Continue to Show Durable Responses as a Single Agent

02/06/2018 - 22:05

- In 179 Relapsed or Refractory IDH1m AML Patients, Primary Endpoint of CR+CRh Rate of 31.8% with a Median Duration CR+CRh of 8.2 Months - - Updated Data Suggest that R/R AML Patients with IDH1-Mutation Clearance Who [...]

New Novartis data presented at ASCO find nearly half of CML patients treated with Tasigna® remain in remission almost three years after stopping therapy

02/06/2018 - 22:01

ENESTop and ENESTfreedom data evaluate Treatment-free Remission (TFR) rates at 144 weeks among eligible Ph+ CML-CP patients who stopped Tasigna ® Findings further support durability and safety of TFR with Tasigna; [...]

Jounce Therapeutics Presents Preliminary Efficacy Data from Ongoing Phase 1/2 ICONIC Trial of JTX-2011 in Patients with Advanced Cancers

02/06/2018 - 22:00

Company to Host Investor Event and Live Webcast on Monday, June 4 CAMBRIDGE, Mass., June 02, 2018 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ:JNCE), a clinical-stage company focused on the discovery and [...]

Loxo Oncology Announces Positive Interim Clinical Data from LOXO-292 Dose Escalation Trial in RET-Altered Cancers Presented at the American Society of Clinical Oncology Annual Meeting

02/06/2018 - 15:00

– 77% Overall Response Rate in RET Fusion Cancers and 45% Overall Response Rate in RET Mutated Medullary Thyroid Cancer (MTC) – – Activity Observed Independent of RET Alteration, Tumor Type (Lung, Thyroid, Pancreas), or [...]

G1 Therapeutics Presents Phase 1b Data on G1T38 in Combination with Faslodex for Treatment of Breast Cancer at 2018 American Society of Clinical Oncology (ASCO) Annual Meeting

02/06/2018 - 15:00

RESEARCH TRIANGLE PARK, N.C., June 02, 2018 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq:GTHX), a clinical-stage oncology company, today announced that preliminary data from its Phase 1b/2a clinical trial of G1T38 [...]

Updated Myxoid/Round Cell Liposarcoma Data with NY-ESO, Presented at ASCO Annual Meeting, Further Supports Promising Benefit: Risk Profile

02/06/2018 - 14:00

PHILADELPHIA and OXFORD, United Kingdom, June 02, 2018 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, presented initial data from the ongoing pilot study of [...]

National Research Corporation Declares Quarterly Dividend

01/06/2018 - 23:33

Lincoln, Nebraska, June 01, 2018 (GLOBE NEWSWIRE) -- National Research Corporation (NASDAQ:NRC)) today announced that its Board of Directors has declared a quarterly cash dividend of $0.17 (seventeen cents) per share [...]

Flexion Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

01/06/2018 - 23:13

BURLINGTON, Mass., June 01, 2018 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced a grant of inducement stock options to eight new employees for an aggregate of 50,000 shares of common stock [...]

Paratek Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

01/06/2018 - 22:30

BOSTON, June 01, 2018 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq:PRTK), a biopharmaceutical company focused on the development and commercialization of innovative therapies based upon tetracycline [...]

Zogenix Reports Granting of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

01/06/2018 - 22:24

EMERYVILLE, Calif., June 01, 2018 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company developing therapies for the treatment of rare central nervous system (CNS) disorders, today announced that it [...]

FDA Classifies HeartWare(TM) HVAD(TM) Systems Unexpected Power Source Switching as Class I Recall

01/06/2018 - 22:23

DUBLIN - June 1, 2018 - The United States Food and Drug Administration (FDA) has classified Medtronic plc's (NYSE: MDT) recent voluntary urgent field action related to the HeartWare(TM) HVAD(TM) System unexpected power [...]

Reata Selected to Present Early-Stage Programs at the BIO International Convention

01/06/2018 - 22:15

IRVING, Texas, June 01, 2018 (GLOBE NEWSWIRE) -- Reata Pharmaceuticals, Inc. (Nasdaq:RETA), a clinical-stage biopharmaceutical company, today announced that Chief Development Officer, Keith Ward, Ph.D., will present at [...]

Agios Presents Data from Phase 1 Dose-Escalation Study of AG-881 in Patients with IDH Mutant Positive Advanced Glioma and Other Solid Tumors

01/06/2018 - 22:15

- Favorable Safety Profile at Dose Levels Below 100 mg; 10 mg and 50 mg Doses Under Evaluation in Recently Initiated Glioma Perioperative Study - - Evidence of Prolonged Disease Control Observed in Non-Enhancing Glioma [...]

OmniSeq and LabCorp Launch OmniSeq Advance℠ Assay

01/06/2018 - 22:11

New test combines both targeted therapy and immune-oncology biomarkers in a single test with 99% actionability, providing benefits for the treatment of patients and the development of new therapies CHICAGO, June 01, [...]